

10/501,122


***** Welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:34:32 ON 28 JUN 2005

=> file reg

=>

Uploading C:\Program Files\Stnexp\Queries\10501122.str



chain nodes :

13 14 15 16 18 19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

6-16 8-13 13-14 13-15 15-16 16-19 16-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

13-14 13-15 15-16 16-19 16-18

exact bonds :

6-16 8-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

G1:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> dis l1

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

L2 11 SEA SSS SAM L1

=> s l1 full

L3 155 SEA SSS FUL L1

=> file caplus

=> s l3

L4 35 L3

=> s l4 and pd<april 2002

22348260 PD<APRIL 2002

(PD<20020400)

L5 21 L4 AND PD<APRIL 2002

=> s l4 not l5

L6 14 L4 NOT L5

=> dis l6 1-14 bib abs

L6 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:324138 CAPLUS

DN 142:392428

TI Preparation of heterocyclic compounds as antifungal agents

IN Nakamoto, Kazutaka; Tsukada, Itaru; Tanaka, Keigo; Matsukura, Masayuki;
Haneda, Toru; Inoue, Satoshi; Ueda, Norihiro; Abe, Shinya; Hata, Katsura;
Watanabe, Naoaki

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 418 pp.

CODEN: PIXXD2

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005033079	A1	20050414	WO 2004-JP14063	20040927
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2003-342273 A 20030930
JP 2004-68186 A 20040310

GI



AB The title compds., e.g. I [ring A1 is optionally substituted 3-pyridyl, optionally substituted quinolyl, etc.; X1 is NHCO, etc.; and ring E is furyl, thienyl, pyrrolyl, Ph, pyridyl, tetrazolyl, thiazolyl, or pyrazolyl; provided that A1 may have one to three substituents and E has one or two substituents], are prepared 2,6-Diamino-N-(5-(4-fluorophenoxy)furan-2-ylmethyl)nicotinamide was prepared in a multistep process. Compds. of this invention in vitro showed MIC values of 0.1 µg/mL to 6.25 µg/mL against Candida.

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:140809 CAPLUS

DN 142:240423

TI A preparation of antiproliferative 2-(heteroaryl)aminothiazole derivatives

IN Chong, Wesley Kwan Mung; Duvadie, Rohit Kumar; Li, Lin; Yang, Yi

PA Agouron Pharmaceuticals, Inc., USA

SO U.S. Pat. Appl. Publ., 37 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2005038078	A1	20050217	US 2003-639219	20030811
PRAI	US 2003-639219		20030811		
OS	MARPAT 142:240423				


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of 2-(heteroaryl)aminothiazole derivs. of formula I [wherein: R1 is H, alk(en/yn)yl, alkylamino, aryl, or cycloalkyl; R2 and R5 are independently selected from H, halogen, alkyl,

NH₂, SMe, or NO₂, etc.; R₃ and R₄ are independently selected from H, halogen, methoxy, or alkyl], useful as antiproliferative agents. For instance, nicotinamide derivative II (inhibition of HCT-116 cell growth: IC₅₀ = 0.007 μ M) was prepared via amidation of nicotinic acid derivative III by (N-methyl-pyrrolidin-2S-yl)methylamine with a yield of 60%.

L6 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:44250 CAPLUS
 DN 142:273352
 TI Synthesis and structure-activity relationships of benzyloxyphenyl derivatives as a novel class of NCX inhibitors: effects on heart failure
 AU Kuramochi, Takahiro; Kakefuda, Akio; Yamada, Hiroyoshi; Ogiyama, Takashi; Taguchi, Taku; Sakamoto, Shuichi
 CS Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd, Tsukuba, Ibaraki, 305-8585, Japan
 SO Bioorganic & Medicinal Chemistry (2005), 13(3), 725-734
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier Ltd.
 DT Journal
 LA English
 GI



AB In the context of heart failure and myocardial ischemia reperfusion, the activity of the sodium-calcium exchanger can lead to calcium overload, which in turn can lead to contractile dysfunction and arrhythmia. Therefore, NCX is an attractive target for treatment of heart failure and myocardial ischemia reperfusion. We have designed and synthesized a series of benzyloxyphenyl derivs. as potential NCX inhibitors. These derivs. have been evaluated for their inhibitory activity against both the reverse and forward modes of NCX, and two novel potent NCX inhibitors were discovered. Compound I was evaluated for its efficacy on ouabain-induced tonotropy and arrhythmia in a heart-failure model.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:14361 CAPLUS
 DN 142:113905
 TI Preparation of heterocyclic methyl sulfone derivatives as β -amyloid protein secretion and production inhibitors
 IN Kubota, Hideki; Yasukouchi, Takanori; Miyauchi, Satoru; Motoki, Kayoko; Saito, Masanori; Iimori, Hitoshi
 PA Daiichi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 345 pp.
 CODEN: PIXXD2
 DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000798	A1	20050106	WO 2004-JP9132	20040629
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2003-187796 A 20030630

JP 2004-99151 A 20040330

OS MARPAT 142:113905

AB The title compds. R1R2R4CXR3 (R1 represents an optionally substituted heterocyclic group; R2 represents an optionally substituted cyclic hydrocarbon group or optionally substituted heterocyclic group; R3 represents an optionally substituted cyclic hydrocarbon group or optionally substituted heterocyclic group; R4 represents hydrogen or C1-6 alkyl; and X represents S, SO, or SO2), N-oxides thereof, S-oxides thereof, salts thereof, or solvates thereof are prepared

2-[[[(4-Chlorophenyl)sulfonyl](cyclohexyl)methyl]-1,4-difluorobenzene was prepared in several steps from 2,5-difluorobenzyl alc. and 4-chlorobenzenethiol. In an in vitro assay for β -amyloid protein production inhibiting activity, compds. of this invention showed IC50 values of ≤ 5 nM to 500 nM.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:740294 CAPLUS

DN 141:260769

TI Preparation of aminoheteroaryl compounds as protein kinase inhibitors

IN Cui, Jingjong Jean

PA Sugen, Inc., USA; Bhumralkar, Dilip; Botrous, Iriny; Chu Ji Yu; Funk, Lee A; Hanau, Cathleen Elizabeth; Harris, G. Davis, Jr.; Jia, Lei; et al.

SO PCT Int. Appl., 312 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004076412	A2	20040910	WO 2004-US5495	20040226
	WO 2004076412	A3	20041229		
	W:				
	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,				

BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

US 2005009840 A1 20050113 US 2004-786610 20040226
 PRAI US 2003-449588P P 20030226
 US 2004-540229P P 20040129
 OS MARPAT 141:260769
 GI



AB The title aminopyridines and aminopyrazines [I; Y = N; CR11; R1 = aryl, heteroaryl, cycloalkyl, etc.; R2 = H, halo, alkyl, cycloalkyl, etc.; A1 = (CR9R10)nA2 (with provisos); R9, R10 = H, halo, alkyl, cycloalkyl, etc.; n = 0-4; A2 = aryl, heteroaryl, cycloalkyl, heterocyclic; R11 = halo, alkyl, alkoxy, etc.] which have activity as protein kinase inhibitors, including as inhibitors of c-MET (IC50 values given), were prepared E.g., a multi-step synthesis of 3-(3-methoxybenzyloxy)-5-phenylpyridin-2-amine, was given.

L6 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:589549 CAPLUS

DN 141:140450

TI Preparation of 2-oxypyridin-3-yl thia(di)azoles as Cdk2 and Cdk5 kinase inhibitors for the treatment of cell proliferation-related disorders

IN Zhong, Wenge; Norman, Mark Henry; Kaller, Matthew; Nguyen, Thomas; Rzasa, Robert Michael; Tegley, Christopher; Wang, Hui-Ling

PA Amgen Inc., USA

SO PCT Int. Appl., 317 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004060890	A1	20040722	WO 2003-US41388	20031222
	WO 2004060890	C1	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2004147561 A1 20040729 US 2003-736289 20031212
 PRAI US 2002-436787P P 20021227
 US 2003-736289 A 20031212
 OS MARPAT 141:140450
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = O or S; Q = NH₂ and derivs., NHC(:O)H, alkyl-OH and derivs., (un)substituted monocyclic or bicyclic, etc; W = (un)substituted 1,3-thiazolyl, 1,2,4-thiadiazolyl; R₁, R₂, R₃ = independently H, halo, aryl, alk(en/yn)yl, perfluoroalkyl, NO₂, heterocyclyl, NH₂ and derivs., etc.; R₁CCR₂ or R₂CCR₃ = 5-10 membered (un)saturated carbocyclic or heterocyclic and derivs.; with provisos; and pharmaceutically acceptable salts thereof] are disclosed as serine/threonine kinase inhibitors for effective treatment of cell proliferation or apoptosis-mediated diseases (no data). The invention encompasses I and pharmaceutically acceptable derivs. thereof, pharmaceutical compns., and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer, and the like (no data). For example, II was prepared by cyclization of bromoacetylpyridinone (III) (preparation given) with 2-(2-thienylsulfonyl)ethanethioamide in EtOH under microwave conditions at 150° for 5 min. II exhibited Cdk2/cyclin and Cdk5/p25 kinase activity with IC₅₀ values < 0.5 μ M and inhibited cell proliferation of human PC-3 prostate cells, HCT 116 human colon carcinoma cells, or HT 29 human colon carcinoma cells with IC₅₀ < 1 μ M.

L6 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:220316 CAPLUS

DN 140:253567

TI Preparation of pyridones and pyridazinones as adenosine antagonists and pharmaceutical use thereof

IN Tabuchi, Seiichiro; Tsutsumi, Hideo; Sato, Yoshinari; Akahane, Atsushi

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022540	A2	20040318	WO 2003-JP11271	20030903
	WO 2004022540	A3	20040701		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,				
	TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004067955	A1	20040408	US 2003-653129	20030903

PRAI AU 2002-951245
 AU 2002-952245
 OS MARPAT 140:253567
 GI

A 20020906
 A 20021024



AB Pyridazinones or pyridones (shown as I; variables defined below; e.g. II) or a salt thereof are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like. Methods of preparation are claimed and .apprx.160 example preps. of I and 19 of intermediates are included. For example, II was prepared by cyclizing 6-[(E)-1-benzoyl-2-(dimethylamino)ethenyl]-2-isopropyl-3(2H)-pyridazinone with 2-cyanoacetamide. For I: X is -NHC(O)-, -N:C(R4)-; Y is N or CH; R1 is H or (un)substituted lower alkyl; R2 is H or halogen; R3 is H, lower alkyl, lower alkoxy, halogen, hydroxy, cyano, amino, carbamoyl, thiocarbamoyl, aryl, acyl, acylamino or heterocyclic group, each of which may be (un)substituted; R4 is H, lower alkyl, lower alkoxy, halogen, hydroxy, cyano, amino, carbamoyl, acyl, acylamino or -A-R7 wherein A is -CH:CH- or -CH:N-, and R7 is lower alkyl, lower alkoxy, hydroxy, cyano, acyl, aryl(lower)alkoxy or acyloxy, each of which may be (un)substituted; R5 is H, lower alkyl, lower alkoxy, halogen, hydroxy, each of which may be (un)substituted; and R6 is H or halogen. A1 and A2 adenosine receptor binding (K_i , nM) by 8 examples of I are tabulated; 5 of these I were also tested for anticatalepsy activity in mice.

L6 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:143146 CAPLUS
 DN 140:181441

TI Preparation of antiproliferative 2-(pyridylamino)thiazole compounds
 IN Chong, Wesley Kwan Mung; Duvadie, Rohit Kumar; Li, Lin; Yang, Yi
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

PATENT NO.



KIND

DATE

APPLICATION NO.

DATE

PI WO 2004014904 A1 20040219 WO 2003-IB3181 20030729
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRAI US 2002-402408P P 20020809
 OS MARPAT 140:181441
 GI



AB Thiazole derivs. of formula I [R1 = H, alkenyl, alkylamino, aryl, heteroaryl, cycloalkyl, etc.; R2, R5 = H, halo, alkyl, OMe, OH, amino, SH, SMe, etc.; R3, R4 = H, halo, OMe, alkyl] are prepared. The compds. and pharmaceutical compns. containing them may be used in inhibiting and/or modulating protein kinases, in treating or preventing diseases associated with protein kinases, and/or in treating or preventing cellular proliferative diseases. Thus, II was prepared, and had IC50 and IC90 of 0.0026 and 0.0057 μ M resp. against HCT-116 cells.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:777760 CAPLUS

DN 139:276823

TI Preparation of pyridinyl amides and advantageous compositions thereof for use as fungicides

IN Foor, Stephen Ray



PA E. I. Du Pont de Nemours & Co., USA; Walker, Susannah Hf

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080576	A2	20031002	WO 2003-US8179	20030318
	WO 2003080576	A3	20040325		
	WO 2003080576	C1	20050324		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP	1485355	A2	20041215	EP 2003-711615	20030318
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR	2003008366	A	20050125	BR 2003-8366	20030318
US	2005020643	A1	20050127	US 2004-501122	20040709
PRAI	WO 2002-365765P	P	20020319		
	WO 2003-US8179	W	20030318		
OS	MARPAT 139:276823				
GI					



AB The title compds. [I; R1, R2 = H, alkyl; R5, R6 = alkyl, alkenyl, cycloalkyl, etc.; m and n = 1-4], useful for controlling plant diseases caused by fungal plant pathogens, were prepared E.g., a 4-step synthesis of II (starting from 5-bromo-2-pyridone) which showed 100% disease control in tests against *Plasmopara viticola* and *Phytophthora infestans*, was given. Compns. for controlling plant diseases caused by fungal plant pathogens are described, comprising: (a) at least one compound I, and (b) at least one compound selected from the group consisting of (b1) alkylenebis(dithiocarbamate) fungicides; (b2) compds. acting at the bcl

complex of the fungal mitochondrial respiratory electron transfer site; (b3) cymoxanil; (b4) compds. acting at the demethylase enzyme of the sterol biosynthesis pathway; (b5) morpholine and piperidine compds. that act on the sterol biosynthesis pathway; (b6) phenylamide fungicides; (b7) pyrimidinone fungicides; (b8) phthalimides; and (b9) fosetyl-aluminum. Also disclosed are methods for controlling plant diseases caused by fungal plant pathogens that involves applying an effective amount of the combinations described.

L6 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:777484 CAPLUS

DN 140:141086

TI Synergistic fungicide compositions containing N-[(2-pyridinyl)methyl]-3-pyridinecarboxamide derivatives and one or more further fungicides

IN Foor, Stephen Ray; Walker, Michael Paul

PA E.I. Du Pont De Nemours and Company, USA

SO PCT Int. Appl., 47 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003079787	A1	20031002	WO 2003-US8186	20030318
	WO 2003079787	C2	20040212		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1484969	A1	20041215	EP 2003-716658	20030318
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003008459	A	20050118	BR 2003-8459	20030318
	US 2005009889	A1	20050113	US 2004-501853	20040709
PRAI	US 2002-365766P	P	20020319		
	WO 2003-US8186	W	20030318		
OS	MARPAT 140:141086				
GI					



AB Compns. for controlling plant diseases caused by fungal plant pathogens comprise: (a) at least one compound I (Markush included), including all geometric and stereoisomers, N-oxides and agriculturally suitable salts

thereof; and (b) at least one compound selected from the group consisting of (b1) alkylenebis(dithiocarbamate) fungicides; (b2) compds. acting at the bcl complex of the fungal mitochondrial respiratory electron transfer site; (b3) cymoxanil; (b4) compds. acting at the demethylase enzyme of the sterol biosynthesis pathway; (b5) morpholine and piperidine compds. that act on the sterol biosynthesis pathway; (b6) phenylamide fungicides; (b7) pyrimidinone fungicides; (b8) phthalimides; and (b9) fosetyl-aluminum. The above fungicidal compns. are particularly useful in control of plant diseases caused by *Phytophthora infestans* and *Plasmopara viticola*.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:23106 CAPLUS

DN 138:83329

TI Use of metal ion chelates in validating biological molecules as drug targets in test animal models

IN Rist, Oystein; Hogberg, Thomas; Holst Lange, Birgitte; Schwartz, Thue W.; Elling, Christian E.

PA 7TM Pharma A/S, Den.

SO PCT Int. Appl., 247 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003003009	A1	20030109	WO 2002-DK456	20020628
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002054077	A2	20020711	WO 2001-DK867	20011221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	DK 2001-1026	A	20010629		
	DK 2001-1027	A	20010629		
	DK 2001-1028	A	20010629		
	DK 2001-1030	A	20010629		
	DK 2001-1031	A	20010629		
	US 2001-301931P	P	20010629		
	WO 2001-DK867	A	20011221		
	WO 2000-EP13389	W	20001229		
	DK 2001-536	A	20010330		

US 2001-280237P P 20010330

OS MARPAT 138:83329

AB The invention discloses the use of chemical compds. or selections of chemical compds. (libraries) of the general Formula R1XFY(R1)GZR1 [F, G = N, O, S, Se, P; X, Y, Z = (un)branched C1-12 alkyl, aryl, heteroaryl, etc.; R1 = ABC; A = coupling or connecting moiety; B = spacer moiety; C = functional group] for in vivo methods for testing or validating the physiol. importance and/or the therapeutic or pharmacol. potential of biol. target mols., notably proteins such as, e.g., receptors and especially 7TM receptors

in

test animals expressing the biol. target mol. with, notably, a silent, engineered metal ion site. Use of specific metal ion binding sites of a generic nature in specific biol. target mols. such as, e.g. transmembrane proteins wherein the metal ion binding site is capable of forming a complex with a metal ion is also described. Also disclosed are chemical compds. or libraries suitable for use in methods for improving the in vivo pharmacokinetic behavior of metal ion chelates (e.g. the absorption pattern, the plasma half-life, the distribution, the metabolism and/or the elimination of the metal ion chelates). In order to improve the efficacy of the impact of the metal ion chelate on the biol. target mol. after administration of the metal ion chelate in vivo to a test animal, it is advantageous e.g. to increase the period during which the metal ion chelate is in the circulatory system and/or localized at the target. Further disclosed are metal ion-chelating compds. designed to be suitable for use in a target validation process according to the invention, as well as libraries of at least two or more of such metal ion-chelating compds.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:23105 CAPLUS

DN 138:83328

TI Metal ion binding-based chemical libraries useful for drug discovery processes

IN Hoegberg, Thomas; Rist, Oystein; Hjelmencrantz, Anders; Moldt, Peter; Elling, Christian E.; Schwartz, Thue W.; Gerlach, Lars Ole; Holst Lange, Birgitte

PA 7TM Pharma A/S, Den.

SO PCT Int. Appl., 242 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003003008	A1	20030109	WO 2002-DK455	20020628
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	DK 2001-1029	A	20010629		
	DK 2001-1032	A	20010629		

DK 2001-1033 A 20010629
 DK 2001-1034 A 20010629
 DK 2001-1035 A 20010629
 US 2001-301989P P 20010629
 US 2001-301990P P 20010629

OS MARPAT 138:83328

AB The invention discloses the use of chemical compds. or selections of chemical compds. (libraries) of the general formula R1XFY(R1)GZR1 [F, G = N, O, S, Se, P; X, Y, Z = (un)branched C1-12 alkyl, (hetero)aryl, etc.; R1 = H, ABC; A = coupling or connecting moiety; B = spacer moiety; C = functional group] for in vivo methods for testing or validating the physiol. importance and/or the therapeutic or pharmacol. potential of biol. target mols., notably proteins such as, e.g., receptors and especially 7TM receptors

in

test animals expressing the biol. target mol. with, notably, a silent, engineered metal ion site. Use of specific metal ion binding sites of a generic nature in specific biol. target mols. such as, e.g. transmembrane proteins wherein the metal-ion binding site is capable of forming a complex with a metal ion is also described. The invention provides chemical compds. or libraries suitable for use in methods for improving the in vivo pharmacokinetic behavior of metal-ion chelates (e.g. the absorption pattern, the plasma half-life, the distribution, the metabolism and/or the elimination of the metal ion chelates). In order to improve the efficacy of the metal ion chelates impact on the biol. target mol. after administration of the metal ion chelate in vivo to a test animal, it is advantageous e.g. to increase the time period during which the metal ion chelate is in the circulatory system and/or localized at the target. Metal ion chelating compds., which are designed to be suitable for use in a target validation process according to the invention and to libraries of at least two or more of such metal-ion chelating compds. are disclosed.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:594842 CAPLUS

DN 137:154859

TI Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes

IN Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 285 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060896	A1	20020808	WO 2001-IB2726	20011224
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2436544	AA	20020808	CA 2001-2436544	20011224

EE 200300361	A	20031215	EE 2003-361	20011224
EP 1373258	A1	20040102	EP 2001-273558	20011224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016845	A	20040225	BR 2001-16845	20011224
JP 2004518689	T2	20040624	JP 2002-561464	20011224
NZ 526531	A	20050225	NZ 2001-526531	20011224
US 2003027845	A1	20030206	US 2002-66503	20020131
US 6828333	B2	20041207		
ZA 2003004893	A	20040624	ZA 2003-4893	20030624
BG 107960	A	20041029	BG 2003-107960	20030701
NO 2003003399	A	20030925	NO 2003-3399	20030730
US 2005049258	A1	20050303	US 2004-918820	20040813
PRAI US 2001-265304P	P	20010131		
WO 2001-IB2726	W	20011224		
US 2002-66503	A3	20020131		
OS MARPAT 137:154859				
GI				



I



II

AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl, Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F, Cl, alkynyl, R16,



OR16, SOO-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)saturated monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepared as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole•H₂O and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide•HCl in DMF/CH₂Cl₂ to give the pyridinecarboxamide II (R = Me) in 38% yield. Saponification using aqueous LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addition, I may be used in combination therapy with a wide variety of other therapeutic agents.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:275966 CAPLUS
DN 136:294739
TI Preparation of pyridinyl-substituted benzamides as Apo B secretion inhibitors
IN Takasugi, Hisashi; Terasawa, Takeshi; Inoue, Yoshikazu; Nakamura, Hideko; Nagayoshi, Akira; Ohtake, Hiroaki; Furukawa, Yoshiro; Mikami, Masafumi; Hinoue, Kazumasa; Ohtsubo, Makoto
PA Fujisawa Pharmaceutical Co., Ltd., Japan; Daiso Co., Ltd.
SO PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028835	A1	20020411	WO 2001-JP8581	20010928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2425097	AA	20020411	CA 2001-2425097	20010928
AU 2001092315	A5	20020415	AU 2001-92315	20010928
EP 1326835	A1	20030716	EP 2001-972612	20010928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001014657	A	20030930	BR 2001-14657	20010928
JP 2004510763	T2	20040408	JP 2002-532421	20010928
NZ 525591	A	20040430	NZ 2001-525591	20010928
NO 2003001540	A	20030605	NO 2003-1540	20030404
ZA 2003003371	A	20040730	ZA 2003-3371	20030430

US 2004058903	A1	20040325	US 2003-381737	20030903
PRAI AU 2000-583	A	20001005		
AU 2001-6666	A	20010727		
WO 2001-JP8581	W	20010928		
OS MARPAT 136:294739				
GI				




AB Title compds. I [wherein R1 and R2 = independently alkyl, alkenyl, acyl, amino, (cyclo)alkoxy, aryl(oxy), sulfoxy, mercapto, sulfo, H, halo, NO₂, CN, or OH; or R1R2 = a ring; Q1 = N or CH; L = (un)substituted unsatd. 3 to 10-membered heterocyclic group; X = (un)substituted monocyclic (hetero)arylene; Y = (A1)_m(A2)_n(A4)_k; Z = direct bond, CH₂, NH, or O; R = H or alkyl; A1 = (un)substituted alkylene or alkenylene; A2 = NR₃, CONR₃, NHCONH, CO₂, O, O(CH₂)₂NR₃, S, SO, or SO₂; A4 = alkylene, alkenylene, or alkynylene; R₃ = H or suitable substituent; k, m, and n = independently 0 or 1; or a salt thereof] were prepared as apolipoprotein B (Apo B) secretion inhibitors. For example, to a suspension of N-(4-aminophenyl)-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide, 2-pyridinylacetic acid•HCl, and HOBT•H₂O in CH₂Cl₂ was added to WSC•HCl, followed by TEA at 5°C. The mixture was stirred at room temperature for 24 h and worked up to give II. The latter inhibited Apo B secretion by 100% at 10⁻⁶ M in HepG2 cells and lowered cholesterol by 83% and triglyceride by 35% after 2 h at a dose of 32 mg/kg in ddY-mice. I are useful for the prophylaxis and treatment of diseases or conditions resulting from elevated circulating levels of Apo B, such as hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, pancreatitis,

non-insulin dependent diabetes mellitus, obesity, coronary heart diseases, myocardial infarction, stroke, restenosis, and Syndrome X.


RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis 15 1-21 bib abs hitstr

L5 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:675130 CAPLUS
DN 138:265330
TI 2,5-Pyridinedicarboxylic acid derivatives as non-Nucleosidic Reverse transcriptase inhibitors of Hepatitis B Virus
AU Lee, Jin Soo; Shim, Hyung Soo; Park, Yong Kyun; Park, Sang Jin; Shin, Joon Su; Yang, Wang Yong; Lee, Hak Dong; Park, Whui Jung; Chung, Yong Ho; Lee, Sang Wook
CS Central Research Laboratory, DongWha Pharm. Ind. Co. Ltd., Seoul, 430-017, S. Korea
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(19), 2715-2717
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB 2,5-Pyridinedicarboxylic acid derivs. were found to be the potent non-nucleoside inhibitors of hepatitis B virus (HBV) with IC50 ≤0.01 µg/mL in a reverse transcriptase inhibitory effect. And they showed the low toxicity compared with the nucleoside analogs.
IT **250145-50-7P 503568-77-2P 503568-79-4P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(2,5-pyridinedicarboxylic acid derivs. as non-nucleosidic reverse transcriptase inhibitors of hepatitis B virus)
RN 250145-50-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[4-[3-(ethylamino)-2-pyridinyl]-1-piperazinyl]carbonyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 503568-77-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[4-(3-amino-2-pyridinyl)-1-piperazinyl]carbonyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 503568-79-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:220560 CAPLUS
DN 136:263098
TI Preparation of pyridinyl amides and imides for use as fungicides
IN Neubert, Timothy Donald; Piotrowski, David Walter; Walker, Michael Paul
PA E. I. Du Pont de Nemours & Co., USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022583	A2	20020321	WO 2001-US28971	20010917 <--
	WO 2002022583	A3	20020718		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
	US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2002011233	A5	20020326	AU 2002-11233	20010917 <--
BR	2001014122	A	20030701	BR 2001-14122	20010917
EP	1322614	A2	20030702	EP 2001-979248	20010917
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP	2004518629	T2	20040624	JP 2002-526836	20010917
ZA	2003000643	A	20040219	ZA 2003-643	20030123
US	2004044040	A1	20040304	US 2003-380243	20030312
PRAI	US 2000-233374P	P	20000918		
	US 2001-277199P	P	20010320		
	WO 2001-US28971	W	20010917		
OS	MARPAT 136:263098				
GI					



AB Title compds. [ACRR1R2YWB; A is a substituted pyridinyl ring; B is a substituted pyridinyl ring; W is C:L, SOn; L = O, S, CXR4; R1 and R2 are each independently = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, each optionally substituted; Y = NR3; R3 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxy carbonyl, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl; R4 = C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, each optionally substituted; X = O, S; n = 1, 2; provided that when W is CO and R1, R2 and R3 are H; then B is other than 4-trifluoromethyl-3-pyridinyl, 2-chloro-4-pyridinyl and 2,6-dihalo-4-pyridinyl], N-oxides and agriculturally suitable salts are prepared and disclosed which are useful as fungicides. Also disclosed are compns. containing the compds. I and a method for controlling plant diseases caused by fungal plant pathogens that involves applying an effective amount of a compound I.


IT 404875-64-5P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridinyl amides and imides for use as fungicides)

RN 404875-64-5 CAPLUS

CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-6-methyl- (9CI) (CA INDEX NAME)



IT 326475-70-1P 326475-74-5P 326475-80-3P

326475-82-5P 326475-97-2P 326475-99-4P

326476-01-1P 404875-61-2P 404875-62-3P

404875-63-4P 404875-65-6P 404875-66-7P

404875-67-8P 404875-68-9P 404875-69-0P

404875-70-3P 404875-71-4P 404875-72-5P

404875-73-6P 404875-74-7P 404875-75-8P

404875-76-9P 404875-77-0P 404875-78-1P

404875-79-2P 404875-80-5P 404875-81-6P

404875-82-7P 404875-83-8P 404875-84-9P

404875-89-4P 404875-93-0P 404875-94-1P

404875-95-2P 404875-96-3P 404876-52-4P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)

(preparation of pyridinyl amides and imides for use as fungicides)


RN 326475-70-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 326475-74-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 326475-80-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)




RN 326475-82-5 CAPLUS

CN 3-Pyridinecarboxamide, 5,6-dichloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 326475-97-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 326475-99-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 326476-01-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 404875-61-2 CAPLUS

CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[(3,5-dichloro-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404875-62-3 CAPLUS

CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[1-(3,5-dichloro-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404875-63-4 CAPLUS

CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[(3,5-dichloro-2-pyridinyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 404875-65-6 CAPLUS

CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[1-(3,5-dichloro-2-pyridinyl)ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 404875-66-7 CAPLUS

CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 404875-67-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[(5-bromo-3-chloro-2-pyridinyl)methyl]-2,4-dichloro- (9CI) (CA INDEX NAME)




RN 404875-68-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[1-(5-bromo-3-chloro-2-pyridinyl)ethyl]-2,4-dichloro- (9CI) (CA INDEX NAME)




RN 404875-69-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[(5-bromo-3-chloro-2-pyridinyl)methyl]-2,4-dichloro-6-methyl- (9CI) (CA INDEX NAME)




RN 404875-70-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[1-(5-bromo-3-chloro-2-pyridinyl)ethyl]-2,4-dichloro-6-methyl- (9CI) (CA INDEX NAME)




RN 404875-71-4 CAPLUS

CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 404875-72-5 CAPLUS
 CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[(1R)-1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 404875-73-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)



RN 404875-74-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-5-(phenylethynyl)- (9CI) (CA INDEX NAME)




RN 404875-75-8 CAPLUS
 CN 3-Pyridinecarboxamide, 2-bromo-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 404875-76-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-1,2-dihydro-6-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 404875-77-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-methyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 404875-78-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-methyl-6-(pentafluoroethyl)- (9CI) (CA INDEX NAME)




RN 404875-79-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-methoxy-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 404875-80-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-(methoxymethyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 404875-81-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-phenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 404875-82-7 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 404875-83-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 404875-84-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 404875-89-4 CAPLUS
 CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[(1S)-1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404875-93-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 404875-94-1 CAPLUS
 CN 3-Pyridinecarboxamide, 2,6-dichloro-N-[[3-chloro-5-(trifluoromethyl)-2-

pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404875-95-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-amino-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404875-96-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl)methyl]-2-ethoxy- (9CI) (CA INDEX NAME)



RN 404876-52-4 CAPLUS

CN 3-Pyridinecarboxamide, 2,4-dichloro-N-[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:142677 CAPLUS


DN 136:200106

TI Preparation of 2-aminopyridine derivatives as adenosine receptor antagonists

IN Harada, Hitoshi; Asano, Osamu; Miyazawa, Shuhei; Ueda, Masato; Yasuda, Masahiro; Yasuda, Nobuyuki

PA Eisai Co., Ltd., Japan
 SO PCT Int. Appl., 128 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014282	A1	20020221	WO 2001-JP6870	20010809 <--
	W: AU, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	AU 2001077741	A5	20020225	AU 2001-77741	20010809 <--
	CA 2417846	AA	20030130	CA 2001-2417846	20010809
	EP 1308441	A1	20030507	EP 2001-955633	20010809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	RU 2250898	C2	20050427	RU 2003-106397	20010809
	ZA 2003000482	A	20040510	ZA 2003-482	20030117
	US 2004006082	A1	20040108	US 2003-333689	20030123
	US 6750232	B2	20040615		
	NO 2003000637	A	20030410	NO 2003-637	20030207
PRAI	JP 2000-245056	A	20000811		
	WO 2001-JP6870	W	20010809		
OS	MARPAT 136:200106				
GI					



AB The title compds. I [R1 is cyano, carboxyl, or optionally substituted carbamoyl; R2 is hydrogen, hydroxyl, optionally substituted C1-6 alkoxy, an optionally substituted C6-14 aromatic carbocyclic group, or an optionally substituted 5- to 14-membered aromatic heterocyclic group; and R3 and R4 are each independently an optionally substituted C6-14 aromatic carbocyclic group, a 5- to 14-membered nonarom. heterocyclic group, a 5- to 14-membered aromatic heterocyclic group, or the like] are prepared. In an assay for the A2b receptor antagonism, 2-amino-6-(2-furyl)-5-(4-pyridyl)-3-pyridinecarbonitrile showed IC50 of 2.7 nM.


IT **400761-96-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyridine derivs. as adenosine receptor antagonists)

RN 400761-96-8 CAPLUS

CN [3,3'-Bipyridine]-5-carboxamide, 6-amino-1'-ethyl-2-(2-furanyl)-1',6'-dihydro-6'-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:581887 CAPLUS
DN 135:152812
TI Preparation of nicotinamide benzofused-heterocyclyl derivatives as
selective inhibitors of PDE4 isozymes
IN Marfat, Anthony; Chamber, Robert James
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 196 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001057036	A1	20010809	WO 2001-IB124	20010130 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2398182	AA	20010809	CA 2001-2398182	20010130 <--
BR 2001007964	A	20021029	BR 2001-7964	20010130
EP 1252158	A1	20021030	EP 2001-901333	20010130
EP 1252158	B1	20050420		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 200201880	T2	20021121	TR 2002-200201880	20010130
JP 2003522176	T2	20030722	JP 2001-557868	20010130
EE 200200425	A	20031015	EE 2002-425	20010130
NZ 519547	A	20040326	NZ 2001-519547	20010130
AT 293624	E	20050515	AT 2001-901333	20010130
BG 106852	A	20030228	BG 2002-106852	20020620
US 2003186989	A1	20031002	US 2002-181416	20020724
ZA 2002006033	A	20030729	ZA 2002-6033	20020729
NO 2002003613	A	20020930	NO 2002-3613	20020730
PRAI US 2000-179284P	P	20000131		

WO 2001-IB124
OS MARPAT 135:152812
GI

W 20010130

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. [I; m = 0-2; n = 1-2; W = O, Sot (wherein t = 0-2), NR3; Y = CH, CF, NO, etc.; R1, R2 = H, F, Cl, etc.; R3 = H, alkyl, alkoxy, etc.; R4 = H, F, CN, etc.; R5 and R6 are taken together to form II-VI (R7, R8 = H, Me, OH, alkoxy); R9, R10 = H, F, CF3, etc.; R11, R12 = R9, R10, except that at least one of R11 and R12 must be H atom; Q = Ph, pyrrolyl, furanyl, etc.; Z = CN, OH, O(alkyl), etc.], useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, were prepared Thus, amidation of 2-(benzo[2,1,3]oxadiazol-5-yloxy)nicotinic acid (preparation given) with 2-(4-aminomethylphenyl)propan-2-ol afforded 68% the nicotinamide VII.

IT 353281-70-6P 353281-84-2P 353282-24-3P
353282-52-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nicotinamide benzofused-heterocyclyl derivs. as selective inhibitors of PDE4 isoenzymes)


RN 353281-70-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-(2,1,3-benzoxadiazol-5-yloxy)-N-[[5-(1-hydroxy-1-methylethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 353281-84-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-(2,1,3-benzoxadiazol-5-yloxy)-N-[[5-(1-hydroxycyclopropyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 353282-24-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-(2,1,3-benzoxadiazol-5-ylthio)-N-[[5-(1-hydroxy-1-methylethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 353282-52-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[5-(1-hydroxy-1-methylethyl)-2-pyridinyl]methyl]-2-[(2-methyl-2H-benzotriazol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:136944 CAPLUS

DN 134:174247

TI Preparation of fungicidal nitrogen compounds.

IN Cooke, Tracey; Ekwuru, Tennyson; Hardy, David; Millward, Peter; Moloney, Brian; Pettinger, Andrew; Thomas, Peter Stanley; Turner, Richar Michael

PA Aventis CropScience GmbH, Germany

SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001011966	A1	20010222	WO 2000-EP8269	20000811 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000013367	A	20020507	BR 2000-13367	20000811
	EP 1204322	A1	20020515	EP 2000-956481	20000811
	EP 1204322	B1	20050209		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506466	T2	20030218	JP 2001-516329	20000811
	AT 288681	E	20050215	AT 2000-956481	20000811
	US 6630495	B1	20031007	US 2002-49981	20020722
PRAI	GB 1999-19588	A	19990818		
	WO 2000-EP8269	W	20000811		

OS MARPAT 134:174247


AB The fungicidal nitrogen compds. A1CR1R2NR3LA2 and A1CR1R2N:CYA2 [A1 = (un)unsubstituted 2-pyridyl or its N-oxide; A2 = (un)substituted heterocyclyl or carbocyclyl; R1, R2 = alkyl, alkenyl, cyano, nitro, halo, etc.; L = CO, CS, SO2, etc., Y = halo, alkoxy, alkylthio, etc.] are prepared

IT 164341-60-0P 326475-70-1P 326475-71-2P
326475-74-5P 326475-75-6P 326475-80-3P
326475-82-5P 326475-97-2P 326475-98-3P
326475-99-4P 326476-00-0P 326476-01-1P
326476-02-2P 326476-05-5P 326476-27-1P
326476-31-7P

RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as fungicide)


RN 164341-60-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 326475-70-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 326475-71-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 326475-74-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 326475-75-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 326475-80-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)




RN 326475-82-5 CAPLUS

CN 3-Pyridinecarboxamide, 5,6-dichloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 326475-97-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 326475-98-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 326475-99-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 326476-00-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 326476-01-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 326476-02-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]thio]- (9CI) (CA INDEX NAME)




RN 326476-05-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 326476-27-1 CAPLUS

CN 2-Pyridineacetic acid, 3-chloro-α-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 326476-31-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1-piperidinylmethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:840671 CAPLUS
DN 134:95135
TI Comparative quantitative structure-activity study of radical scavengers
AU Vajragupta, Opa; Boonchoong, Preecha; Wongkrajang, Yuwadee
CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mahidol
University, Bangkok, 10400, Thailand
SO Bioorganic & Medicinal Chemistry (2000), 8(11), 2617-2628
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Science Ltd.
DT Journal
LA English
AB Classic and three-dimensional (3-D) QSAR analyses of 13 radical scavengers were performed to derive 2 classic, 2 Apex-3-D and 1 comparative field anal. (CoMFA) models. Two classical models with predictive cross-validated r^2 (Q^2) over 0.96 indicated that the activity was attributed to the electronic COH and ELUMO, steric molar refractivity (MR) and lipophilic log P. Three-dimensional quant. structure-activity relationship (3-D-QSAR) studies were performed by 3-D pharmacophore generation (Apex-3-D) and CoMFA techniques. For Apex-3-D studies, 2 best models with high Q^2 (0.94 and 0.97) were yielded. Structural properties contributing to the activity were not only lipophilic but also the optimum steric property and geometry of side-chain composition. For CoMFA studies, the sp^3 C(+1) probe provided the best Q^2 of 0.79 with steric and electrostatic contributions of 42.3 and 57.7%, resp. The activity of 4 new compds. not included in the derivation were predicted with these models. Although the derived models were from limited data, the statistic relation was predictive. The linear correlations between the exptl. IC50 values and the predicted values from classical and Apex-3-D models were high and significant. The predicted activity of 17 from CoMFA was much lower than the exptl. value; this deviation occurred according to the missing of hydrophobic field in standard CoMFA study. In vitro and ex vivo antilipid peroxidn. in mouse brain and ESR studies of were investigated for the radical-scavenging ability. The difference between the in vitro results, antilipid peroxidn. and ESR and ex vivo results in coumarin series was found. Thus, other properties for good bioavailability besides log P should also be taken into consideration.

IT 25297-40-9 313988-83-9
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(comparative quant. structure-activity study of)


RN 25297-40-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 313988-83-9 CAPLUS

CN 3-Pyridinecarboxamide, 1,6-dihydro-6-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:763739 CAPLUS

DN 134:50997

TI Chroman amide and nicotinyl amide derivatives: inhibition of lipid peroxidation and protection against head trauma

AU Vajragupta, Opa; Toasaksiri, Suwanna; Boonyarat, Chantana; Wongkrajang, Yuvadee; Peungvicha, Penchom; Watanabe, Hiroshi; Boonchoong, Preecha

CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mahidol University, Bangkok, 10400, Thailand

SO Free Radical Research (2000), 32(2), 145-155


CODEN: FRARER; ISSN: 1071-5762

PB Harwood Academic Publishers

DT Journal

LA English

GI



AB A series of chroman amide and nicotinyl amide derivs. was designed and synthesized for the treatment of traumatic and ischemic CNS injury. Five compds. were significantly more potent inhibitors of lipid peroxidn. in

vitro than the reference antioxidant, trolox ($p < 0.01$). Quant. structure activity studies demonstrated that the inhibitory action was related to the ability to donate electrons, charge on hydroxy group and ELUMO, to scavenging radicals and to the lipophilicity log P, which dets. penetration of membrane lipids. ESR study indicated the ability of 12 to scavenge the hydroxyl radicals. The most promising compound, [(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)carbonyl]-3'-(aminoethyl) indole (12), inhibited ex vivo lipid peroxidn. in a head injury model and showed potent in vivo neuroprotective efficacy. Improvement of neurol. recovery within 1 h of injury (grip test score) by as much as 200% was observed together with significant anti-anoxia activity. Compound (I) was a potent antagonist of methamphetamine-induced hypermotility resulting from dopamine release in the mouse brain. These results support the importance of cerebroprotective radical-scavenging agents for the treatment of traumatic injury and anoxia as well as provide addnl. evidence for the role of oxygen radicals and dopamine in brain damage.


IT 25297-40-9P 313988-83-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(chroman amide and nicotinyl amide derivs. inhibit lipid peroxidn. and protect against head trauma)


RN 25297-40-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 313988-83-9 CAPLUS

CN 3-Pyridinecarboxamide, 1,6-dihydro-6-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:736698 CAPLUS


DN 131:337036

TI Preparation of novel 2,5-pyridinedicarboxylic acid derivatives as anti-retroviral agents


IN Yoon, Sung Joon; Lee, Sang Wook; Sim, Hyeong Su; Park, Yong Kyun; Yang, Wang Yong; Kim, Jong Woo; Han, Jae Jin; Yoon, Je In; Park, Sang Jin; Park, Hee Jeoung; Sin, Dong Hyuk; Chang, Hwan Bong

PA Dong Wha Pharm. Ind. Co., Ltd., S. Korea; et al.
 SO PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958526	A1	19991118	WO 1999-KR213	19990501 <--
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9935391	A1	19991129	AU 1999-35391	19990501 <--
	US 6306860	B1	20011023	US 2000-674844	20001107 <--
PRAI	KR 1998-17153	A	19980513		
	KR 1998-19555	A	19980528		
	KR 1998-28258	A	19980714		
	WO 1999-KR213	W	19990501		
OS	MARPAT 131:337036				
GI					



I



II


AB The title compds. [I; R1 = OH, alkyl, cycloalkyl, etc.; R2 = H, Ph, alkyl, etc.; R3 = II (wherein Q = H, alkyl, 2-hydroxyethyl); n = 0-4], useful as anti-retroviral agents, having inhibitory activities against the proliferation of retrovirus such as hepatitis B virus and human immunodeficiency virus, were prepared. Thus, treatment of 6-{1-[3-(isopropylamino)-2-pyridyl]piperazine-4-ylcarbonyl}nicotinic acid (preparation given) in CH₂Cl₂ with Et₃N and pivaloyl chloride followed by the addition of Et₃N and HO(CH₂)₂NH₂ afforded 83% I [R1 = OH; R2 = H; R3 = II; Q = iPr; n = 2] which showed inhibitory activity (e.g., 51% at 0.1 µg/mL) against HBV polymerase in vitro.

IT **250145-49-4P 250145-50-7P 250145-51-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel 2,5-pyridinedicarboxylic acid derivs. as anti-retroviral agents)


RN 250145-49-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 250145-50-7 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[[4-[3-(ethylamino)-2-pyridinyl]-1-piperazinyl]carbonyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 250145-51-8 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[[4-(3-amino-2-pyridinyl)-1-piperazinyl]carbonyl]-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1998:682365 CAPLUS
 DN 129:316147
 TI Preparation of nicotinamides as PDE4 D isoenzymes inhibitors
 IN Marfat, Anthony; Chambers, Robert James; Watson, John Wesley; Cheng, John Bin; Duplantier, Allen Jacob; Kleinman, Edward Fox
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 200 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

PATENT NO.


KIND

DATE

APPLICATION NO.

DATE

PI	WO 9845268	A1	19981015	WO 1998-IB315	19980310 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2285548	AA	19981015	CA 1998-2285548	19980310 <--
	AU 9862273	A1	19981030	AU 1998-62273	19980310 <--
	AU 738037	B2	20010906		
	EP 971894	A1	20000119	EP 1998-904343	19980310 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	TR 9902432	T2	20000121	TR 1999-9902432	19980310 <--
	JP 2000510481	T2	20000815	JP 1998-542528	19980310 <--
	BR 9810733	A	20000912	BR 1998-10733	19980310 <--
	TW 519539	B	20030201	TW 1998-87104586	19980326
	ZA 9802853	A	19991004	ZA 1998-2853	19980403 <--
	HR 980181	B1	20030630	HR 1998-980181	19980403
	US 6380218	B1	20020430	US 1999-308956	19990527
	BG 64356	B1	20041130	BG 1999-103725	19990909
	NO 9904791	A	19991201	NO 1999-4791	19991001 <--
	NO 314182	B1	20030210		
	MX 9909099	A	20000228	MX 1999-9099	19991004 <--
	US 2002111495	A1	20020815	US 2002-62811	20020131
	JP 2004083583	A2	20040318	JP 2003-201291	20030724
PRAI	US 1997-43403P	P	19970404		
	JP 1998-542528	A3	19980310		
	WO 1998-IB315	W	19980310		
	US 1998-105120P	P	19981021		
	US 2001-265240P	P	20010131		
OS	MARPAT 129:316147				
GI					



AB Title compds. [I; wherein m is 0 or 1; n is 0 or 1; o is 0-4; p is 0 or 1; q is 0 or 1; r is 0-4; t is 0 or 1; A is oxygen, NH, or sulfur; B is oxygen or NH; D is oxygen, NH, or alkylamino; E is CH₂, O, NH, SO, SO₂, S; R₁ is H, alkyl, cycloalkyl, aryl, etc.; R₂, R₃ together with attached carbon form carbonyl group or cycloalkyl ring; R₂, R₃, R₄ is independently H, OH, CN, CO₂H, alkyl, etc.; R₅ is cyclic, bicyclic, aryl; R₆, R₇ and R₈ are each independently H, CN, COOH, NO₂, OH, alkyl, etc.] and pharmaceutical composition are prepared for the treatment of respiratory.


allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, Crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

IT 214756-68-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nicotinamides as PDE4 D isoenzymes inhibitors)

RN 214756-68-0 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-pyridinylmethyl)-2-(3-pyridinyloxy)- (9CI)
(CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:464318 CAPLUS

DN 125:114673

TI Preparation of benzyloxyphenylalkylbenzoates and related compounds as analgesics and prostaglandin antagonists

IN Breault, Gloria Ann; Oldfield, John; Tucker, Howard; Warner, Peter

PA Zeneca Limited, UK

SO PCT Int. Appl., 172 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9611902	A1	19960425	WO 1995-GB2417	19951012 <--
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9508622	A	19960412	ZA 1995-8622	19951012 <--
	AU 9536162	A1	19960506	AU 1995-36162	19951012 <--
	EP 733033	A1	19960925	EP 1995-933542	19951012 <--
	EP 733033	B1	19991222		

R: CH, DE, FR, GB, IT, LI

JP 09511529	T2	19971118	JP 1995-513027	19951012 <--
US 5811459	A	19980922	US 1996-647977	19960604 <--
PRAI GB 1994-20557	A	19941012		
WO 1995-GB2417	W	19951012		

OS MARPAT 125:114673

AB Ortho-substituted Ph, naphthyl, and heterocyclic ethers (> 600 compds.) were prepared for use in treating pain mediated by the E-type prostaglandins (no data). Thus, 2-PhCH₂OC₆H₄(CH₂)₃C₆H₄CO₂H-4 was prepared from 2-HOC₆H₄Ac and 4-OCHC₆H₄CO₂Me in 5 steps.

IT 179255-00-6P 179255-14-2P 179255-16-4P

179255-21-1P 179255-32-4P 179255-33-5P


179255-35-7P 179256-57-6P 179256-63-4P

179256-66-7P 179256-95-2P 179257-07-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzyloxyphenylalkylbenzoates and related compds. as analgesics and prostaglandin antagonists)


RN 179255-00-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-[2-(phenylmethoxy)phenyl]ethyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 179255-14-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-[5-(methylthio)-2-(phenylmethoxy)phenyl]ethyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 179255-16-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-[5-bromo-2-(phenylmethoxy)phenyl]ethyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 179255-21-1 CAPLUS


CN 3-Pyridinecarboxamide, 6-[2-[5-bromo-2-(phenylmethoxy)phenyl]ethyl]-2-methoxy-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 179255-32-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-[2-(phenylmethoxy)phenyl]ethenyl]-N-(2-pyridinylmethyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179255-33-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-[5-bromo-2-(phenylmethoxy)phenyl]ethenyl]-N-(2-pyridinylmethyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179255-35-7 CAPLUS


CN 3-Pyridinecarboxamide, 6-[2-[5-(methoxy)phenyl]ethenyl]-N-(2-pyridinylmethyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179256-57-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-[5-bromo-2-(phenylmethoxy)phenyl]ethyl]-1,2-dihydro-2-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 179256-63-4 CAPLUS


CN 3-Pyridinecarboxamide, 1,2-dihydro-2-oxo-6-[2-[2-(phenylmethoxy)phenyl]ethyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 179256-66-7 CAPLUS
 CN 3-Pyridinecarboxamide, 1,2-dihydro-6-[2-[5-nitro-2-(phenylmethoxy)phenyl]ethyl]-2-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 179256-95-2 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-[5-cyano-2-(phenylmethoxy)phenyl]ethyl]-1,2-dihydro-2-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 179257-07-9 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-[5-bromo-2-(phenylmethoxy)phenyl]ethyl]-2-chloro-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1996:367337 CAPLUS
 DN 125:33683
 TI Aromatic amino ethers as pain relieving agents
 IN Breault, Gloria Anne; Oldfield, John; Tucker, Howard; Warner, Peter
 PA Zeneca Limited, UK
 SO PCT Int. Appl., 140 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9603380	A1	19960208	WO 1995-GB1728	19950721 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2192088	AA	19960208	CA 1995-2192088	19950721 <--
	AU 9529883	A1	19960222	AU 1995-29883	19950721 <--
	AU 688541	B2	19980312		
	EP 773930	A1	19970521	EP 1995-925943	19950721 <--
	EP 773930	B1	20001011		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1154106	A	19970709	CN 1995-194340	19950721 <--
	CN 1085663	B	20020529		
	BR 9508335	A	19970930	BR 1995-8335	19950721 <--
	HU 76606	A2	19971028	HU 1996-3338	19950721 <--
	JP 10503487	T2	19980331	JP 1995-505573	19950721 <--
	AT 196898	E	20001015	AT 1995-925943	19950721 <--
	ES 2150577	T3	20001201	ES 1995-925943	19950721 <--
	PT 773930	T	20010131	PT 1995-925943	19950721 <--
	TW 411328	B	20001111	TW 1995-84107606	19950722 <--
	ZA 9506149	A	19960207	ZA 1995-6149	19950724 <--
	FI 9700261	A	19970122	FI 1997-261	19970122 <--
	NO 9700314	A	19970313	NO 1997-314	19970124 <--
	NO 308032	B1	20000710		
	US 5843942	A	19981201	US 1997-776275	19970124 <--
	CN 1286254	A	20010307	CN 2000-104017	20000310 <--
	GR 3034603	T3	20010131	GR 2000-402119	20001012 <--
PRAI	GB 1994-14924	A	19940725		
	GB 1995-1288	A	19950124		
	WO 1995-GB1728	W	19950721		
OS	MARPAT 125:33683				
GI					



I



II

AB The invention relates to compds. I [A = (un)substituted Ph, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, thienyl, thiazolyl, oxazolyl, thiadiazolyl having ≥ 2 adjacent ring C atoms, or bicyclic ring system, provided that the shown sidechains on A are in a 1,2-relationship, and the 3-position is unsubstituted; B, D = (un)substituted ring system; R1 = various groups; R2 = H, alk(en/yn)yl, phenylalkyl, 5- or 6-membered


heteroarylalkyl; R3, R4 = H or alkyl] and their N-oxides, S-oxides, pharmaceutically acceptable salts, and in vivo-hydrolyzable esters and amides. Also claimed are processes for their preparation, intermediates, use as therapeutic agents, and pharmaceutical comps. I are analgesics which are structurally different from NSAIDS and opiates, and which may also possess antiinflammatory, antipyretic, and antidiarrheal properties. For example, condensation of 6-chloropyridazine-3-carboxamide with N-ethyl-N-(2-benzyloxy-5-bromobenzyl)amine-HCl in N-methylpyrrolidinone containing NaHCO₃ at 115° (85%), and hydrolysis of the carboxamide function with NaOH in iso-PrOH (97%), gave title compound II. I generally had pA₂ > 5.3 for inhibition of PGE₂-induced contraction of guinea pig ileum in vitro, and ED₅₀ of 0.01-100 mg/kg orally in the i.p.-induced writhing test.

IT 177757-51-6P 177758-15-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic amino ethers as analgesics)



RN 177757-51-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]methylamino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 177758-15-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[ethyl[[2-(phenylmethoxy)-1-naphthalenyl]methyl]amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:661170 CAPLUS
 DN 123:228228
 TI Aryl-substituted dibenzoxazepine compounds, pharmaceutical compositions
 and methods of use as prostaglandin E2 antagonists and analgesics
 IN Chandrakumar, Nizal S.; Huang, Horng Chih; Mueller, Richard A.
 PA G. D. Searle and Co., USA
 SO U.S., 30 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5420270	A	19950530	US 1993-133681	19931007 <--
	US 5512561	A	19960430	US 1995-402257	19950310 <--
PRAI	US 1993-133681	A3	19931007		
OS	MARPAT 123:228228				
GI					



AB The present invention provides substituted dibenzoxazepine compds. I or a pharmaceutically-acceptable salt thereof, (wherein: X is hydrogen, halogen or CF₃; Y is hydrogen or halogen; Z is oxygen, sulfur, SO, or SO₂; R is CO, CH₂, SO, or SO₂; Ar is aryl; and R₁ is hydrogen, halogen, aryl, alkylaryl, alkenylaryl, alkynylaryl, carboxy, carbonylalkoxy or carbonylaminoalkylaryl, with the proviso that R is not CH₂ when R₁ is carboxy, Ph or alkylphenyl), which are useful as analgesic agents for the treatment of pain, and for the treatment of prostaglandin E₂-mediated diseases, pharmaceutical compns. comprising a therapeutically-effective amount of I in combination with a pharmaceutically-acceptable carrier, a method for eliminating or ameliorating pain in an animal, and a method for treating prostaglandin E₂-mediated diseases in an animal, comprising administering a therapeutically-effective amount I to the animal. Thus, e.g., hydrogenation of 8-chloro-10,11-dihydro-10-[2-[(4-pyridinyl)ethynyl]benzoyl]dibenz[b,f][1,4]oxazepine (preparation given) with Raney-Ni afforded 8-chloro-10,11-dihydro-10-[4-[2Z-(4-pyridinyl)ethenyl]benzoyl]dibenz[b,f][1,4]oxazepine hydrochloride and 8-chloro-10,11-dihydro-10-[4-[2-(4-pyridinyl)ethyl]benzoyl]dibenz[b,f][1,4]oxazepine hydrochloride I.HCl [Z = O, Y = H, X = 8-Cl; R = CO, Ar = 1,4-phenylene, R₁ = 2Z-(4-pyridinyl)ethenyl and 2-(4-pyridinyl)ethyl, resp.] which produced analgesia in 9/10 and 9/10 mice in the writhing assay, resp., and demonstrated PGE antagonism with a dose ratio of EC₅₀ doses of 1.1 and 2.29, resp.


IT **168173-27-1P 168173-37-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(aryl-substituted dibenzoxazepine compds., pharmaceutical compns. and methods of use as prostaglandin E₂ antagonists and analgesics)


RN 168173-27-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(8-chlorodibenz[b,f][1,4]oxazepin-10(11H)-yl)carbonyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 168173-37-3 CAPLUS

CN 3-Pyridinecarboxamide, 4-[(8-chlorodibenz[b,f][1,4]oxazepin-10(11H)-yl)carbonyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




IT 168172-95-0P 168172-99-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aryl-substituted dibenzoxazepine compds., pharmaceutical compns. and methods of use as prostaglandin E2 antagonists and analgesics)


RN 168172-95-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(8-chlorodibenz[b,f][1,4]oxazepin-10(11H)-yl)carbonyl]-N-(2-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 168172-99-4 CAPLUS
 CN 3-Pyridinecarboxamide, 4-[(8-chlorodibenz[b,f][1,4]oxazepin-10(11H)-yl)carbonyl]-N-(2-pyridinylmethyl)-, hydrochloride (2:5) (9CI) (CA INDEX NAME)




● 5/2 HCl

L5 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:648066 CAPLUS
 DN 123:55702
 TI Preparation of pyridinecarboxamide derivatives as biocides
 IN Koyanagi, Tooru; Morita, Masayuki; Yoneda, Tetsuo; Kagimoto, Chiharu
 PA Ishihara Sangyo Kaisha, Japan
 SO Jpn. Kokai Tokkyo Koho, 15 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07025853	A2	19950127	JP 1993-196888	19930714 <--

PRAI JP 1993-196888
OS MARPAT 123:55702
GI

19930714



AB Pyridinecarboxamides I [A = alkanediyl, (un)substituted heterocyclyl; R = H, alkyl; if R = H and A = CH₂, then X ≠ unsubstituted pyridyl, same thienyl, or same furyl] and their salts, useful as insecticides and acaricides, were prepared. Thus, hydrogenation of 2-cyano-5-trifluoromethylpyridine gave 5-trifluoromethyl-2-pyridylmethylamine, condensation of which with 4-trifluoromethyl-3-pyridinecarbonyl chloride gave N-[5-(trifluoromethyl)-2-pyridylmethyl]-4-trifluoromethyl-3-pyridinecarboxamide (II). II showed insecticidal activity against *Myzus persicae*.


IT 164341-40-6P 164341-43-9P 164341-46-2P

164341-48-4P 164341-50-8P 164341-60-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyridinecarboxamide derivs. as biocides)


RN 164341-40-6 CAPLUS

CN 3-Pyridinecarboxamide, 4-(trifluoromethyl)-N-[[5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 164341-43-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6-chloro-2-pyridinyl)methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 164341-46-2 CAPLUS

CN 3-Pyridinecarboxamide, 4-(trifluoromethyl)-N-[[3-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 164341-48-4 CAPLUS

CN 3-Pyridinecarboxamide, 4-(trifluoromethyl)-N-[[6-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 164341-50-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[1-(2-pyridinyl)ethyl]-4-(trifluoromethyl)- (9CI)
(CA INDEX NAME)



RN 164341-60-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:638315 CAPLUS

DN 123:32961

TI Preparation of 4-(trifluoromethyl)pyridine-3-carboxamide derivatives as pesticides


IN Haga, Takahiro; Morita, Masayuki; Suchiibun, Hooru Buraun

PA Ishihara Sangyo Kaisha, Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07010841	A2	19950113	JP 1993-187685	19930621 <--
PRAI	JP 1993-187685		19930621		
OS	MARPAT 123:32961				
GI					



AB The title compds. (I; A = pyridyl, thienyl, furyl), useful as insecticides, nematocides, and acaricides, and for controlling harmful insects of soil, are prepared Thus, 3-cyano-2,6-dihydroxy-4-trifluoromethylpyridine was chlorinated by POCl₃ at 160° for 18 h in an autoclave to give 3-cyano-2,6-dichloro-4-trifluoromethylpyridine which was hydrogenated over PdCl₂ in the presence of AcONa in MeOH at H pressure 230 psi to give 3-cyano-4-trifluoromethylpyridine. The latter compound was hydrolyzed with aqueous NaOH under reflux to give, after acidification with concentrated HCl, 4-trifluoromethylpyridine-3-carboxylic acid


which was chlorinated with SOCl₂ in the presence of DMF to give 4-trifluoromethylpyridine-3-carbonyl chloride. The latter acid chloride was condensed with 3-aminomethylpyridine in CH₂Cl₂ to give a title compound I (A = 3-pyridyl) (II). II at 800 ppm killed 100% adult Myzus persicae on a leaf of an egg plant.

IT **164149-37-5P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of (trifluoromethyl)pyridinecarboxamide derivs. as pesticides)

RN 164149-37-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-pyridinylmethyl)-4-(trifluoromethyl)- (9CI)
 (CA INDEX NAME)



L5 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN



AN 1991:536088 CAPLUS

DN 115:136088

TI Preparation of thiazoles as H₂ antagonists for treatment of ulcer

IN Takasugi, Hisashi; Katsura, Yousuke; Tomishi, Tetsuo; Inoue, Yoshikazu
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO Eur. Pat. Appl., 105 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 417751	A2	19910320	EP 1990-117530	19900912 <--
	EP 417751	A3	19910911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ZA 9006638	A	19910626	ZA 1990-6638	19900821 <--
	AU 9062421	A1	19910321	AU 1990-62421	19900911 <--
	AU 641425	B2	19930923		
	JP 03141270	A2	19910617	JP 1990-245742	19900913 <--
	JP 07030056	B4	19950405		
	CA 2025356	AA	19910316	CA 1990-2025356	19900914 <--
	NO 9004020	A	19910318	NO 1990-4020	19900914 <--
	CN 1050191	A	19910327	CN 1990-107681	19900914 <--
	HU 59135	A2	19920428	HU 1990-5918	19900914 <--
	US 5364871	A	19941115	US 1993-29359	19930310 <--
	US 5371097	A	19941206	US 1993-80051	19930622 <--
PRAI	GB 1989-20977	A	19890915		
	GB 1989-28610	A	19891219		
	GB 1990-12962	A	19900611		
	US 1990-571151	B2	19900823		
	US 1991-668915	B1	19910313		
	US 1992-825832	B1	19920128		
	US 1992-887665	B1	19920526		
OS	MARPAT 115:136088				
GI					



AB Title compds. I; [R1= (substituted) amino, HO, halo, cyano, acyl, heterocyclyl, heterocyclylthio, R4N:CR5; R4 = H, cyano, acyl; R5 = H2N, alkoxy; R2, R3 = H, acyl, (halo)alkyl, R2R3 = alkylene; Y = (halo)pyridyl, thiazolyl; A = bond, alkylene] or a salt thereof, are prepared Et 4-acetylthiazole-2-carboxylate and Br were stirred in MeOH for 8 h at room temperature to give the bromo derivative which with (H2N)2C:NC(S)NH2 in EtOH was refluxed to give the ester salt II. In test for inhibition of stress ulcer in rats, II at 32 mg/kg showed 93.9% inhibition.


IT **135451-93-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiulcer agent or H2-receptor antagonist)

RN 135451-93-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[6-[2-[(aminoiminomethyl)amino]-4-thiazolyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1987:576064 CAPLUS
 DN 107:176064
 TI Preparation of imidazo[1,2-a]pyridines and imidazo[1,5-a]pyrimidines as
 cardiotonics
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 23 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62135473	A2	19870618	JP 1986-290820	19861205 <--
PRAI	GB 1985-30144	A	19851206		
OS	CASREACT 107:176064				
GI					




AB The title compds. [I; R1 = H, alkyl; R2 = H, halo, OH, alkyl, alkoxy, alkylthio, alkylamino; R3 = H, alkyl; R4 = (un)substituted heterocyclyl; X = N, CH; provided R3 = alkyl when R1 = H, R2 = H or alkoxy and R4 = alkoxy-2-pyridyl] were prepared as cardiotonics. A mixture of 2.73 g 1-(2-pyridyl)ethylamine-AcOH and 7.5 mL Me3SiOCMe:NSiMe3 in CH2Cl2 was stirred for 15 min and 2.49 g isonicotinic acid was added to the resulting mixture at 15° and the mixture was stirred for 1 h to give 1.35 g N-[1-(2-pyridyl)ethyl]isonicotinamide (II). A mixt of 3.4 g II and 50 mL POCl3 was refluxed for 2 h to give 0.75 g I (R1 = R2 = H, R3 = Me, R4 = 4-pyridyl, X = CH). This increased max dp/dt value of blood pressure in dog left ventricle by 94% at 1.0 mg/kg i.v.

IT 110859-61-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclization of, imidazopyridine derivative from)

RN 110859-61-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




IT 110859-94-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cardiogenic)

RN 110859-94-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-(acetylamino)-4-methyl-N-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




IT 110859-59-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for cardiogenic imidazopyridine derivative)

RN 110859-59-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1982:603229 CAPLUS

DN 97:203229

TI Hypoglycemic nicotinamide derivatives

PA Chugai Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.


KIND

DATE

APPLICATION NO.

DATE

PI JP 57131719 A2 19820814 JP 1981-17414 19810210 <--
 PRAI JP 1981-17414 19810210
 GI



AB Hypoglycemic formulations contain I (R = H, alkyl, or alkoxy; n = 0 or 1). Thus, N-2-pyridylnicotinamide (II) [13160-07-1] was prepared by adding nicotinic acid-HCl [636-79-3] to a solution consisting of 2-aminopyridine [504-29-0], Et₃N and THF. Hypoglycemic tablets contain II 100, CaHPO₄ 58.5, crystalline cellulose 50, corn starch 40, and Ca stearate 1.5 parts. Oral administration of 200 mg II/kg to mice with exptl. hyperglycemia decreased blood sugar from 564 to 440 mg/dL in 150 min.


IT **25297-40-9P**

RL: PREP (Preparation)

(preparation of, for hypoglycemic formulations)

RN 25297-40-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1976:17095 CAPLUS

DN 84:17095

TI Synthesis of 3-N-(pyridylmethyl) amides of quinolinic acid

AU Biniecki, Stanislaw; Kabzinska, Zofia

CS Dep. Chem. Technol. Pharm. Prod., Sch. Med., Warsaw, Pol.

SO Acta Poloniae Pharmaceutica (1975), 32(3), 265-8

CODEN: APPHAX; ISSN: 0001-6837

DT Journal

LA Polish

OS CASREACT 84:17095

GI For diagram(s), see printed CA Issue.


AB Quinolinic anhydride suspended in CHCl₃ and treated with 2-, 3-, and 4-(aminomethyl)pyridine yielded 44-61% of the corresponding I.

IT **57646-74-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 57646-74-9 CAPLUS

CN 2-Pyridinecarboxylic acid, 3-[[2-(pyridinylmethyl)amino]carbonyl]- (9CI)
 (CA INDEX NAME)




L5 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1974:82691 CAPLUS
 DN 80:82691
 TI Bis(pyridinium quaternary salts)
 IN Edwards, Philip Neil
 PA Imperial Chemical Industries Ltd.
 SO U.S., 8 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3786058	A	19740115	US 1972-234648	19720314 <--
	US 3875174	A	19750401	US 1973-428677	19731227 <--
	US 3875175	A	19750401	US 1973-428678	19731227 <--
	US 3917626	A	19751104	US 1973-428694	19731227 <--
	US 3939169	A	19760217	US 1973-428692	19731227 <--
PRAI	GB 1971-8071	A	19710329		
	US 1972-234648	A3	19720314		
GI	For diagram(s), see printed CA Issue.				
AB	The bactericidal quaternary salts I [R = octyl, decyl, dodecyl, X = (CH ₂) ₂ , (CH ₂) ₃ , CH:CH, NHCONH, CH ₂ NHCO, NHCO; Y = MeSO ₃ , Cl, Br; linkage at 2, 3, 4], are prepared by conventional quaternization of the appropriate bis(pyridine)derivs. Thus, nicotinoyl chloride was treated with 3-(aminomethyl)pyridine and the product quaternized to give I (R = decyl, X = CH ₂ NHCO, linkage at 3-position, Y = MeSO ₃). An addnl. 109 compds. are described.				
IT	39641-91-3P 39641-92-4P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	39641-91-3 CAPLUS				
CN	Pyridinium, 1-octyl-2-[[[(1-octylpyridinium-3-yl)carbonyl]amino]methyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)				

CM 1


CRN 47709-92-2
 CMF C28 H45 N3 O



CM 2

CRN 16053-58-0

CMF C H3 O3 S




RN 39641-92-4 CAPLUS

CN Pyridinium, 1-decyl-2-[[[(1-decylpyridinium-3-yl)carbonyl]amino]methyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 47777-39-9


CMF C32 H53 N3 O




CM 2

CRN 16053-58-0

CMF C H3 O3 S



IT 25297-40-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (quaternization of)
 RN 25297-40-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1973:16041 CAPLUS
 DN 78:16041
 TI Pyridine derivatives
 IN Edwards, Philip Neil
 PA Imperial Chemical Industries Ltd.
 SO Ger. Offen., 63 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2215503	A	19721012	DE 1972-2215503	19720329 <--
	GB 1339764	A	19731205	GB 1971-8071	19710329 <--
	ZA 7201692	A	19721227	ZA 1972-1692	19720313 <--
	CA 982568	A1	19760127	CA 1972-137067	19720314 <--
	IT 1000017	A	19760330	IT 1972-49266	19720327 <--
	FR 2132121	A5	19721117	FR 1972-10827	19720328 <--
	FR 2132121	B1	19751226		
	BR 7201840	A0	19731220	BR 1972-1840	19720328 <--
	BE 781428	A1	19720929	BE 1972-115731	19720329 <--
	NL 7204232	A	19721003	NL 1972-4232	19720329 <--
	HU 164912	P	19740528	HU 1972-IE497	19720329 <--
	ES 401347	A1	19750401	ES 1972-401347	19720329 <--
	AT 323164	B	19750625	AT 1972-2721	19720329 <--
	AT 323169	B	19750625	AT 1973-10644	19720329 <--
	AT 323170	B	19750625	AT 1973-10645	19720329 <--
	CH 575942	A	19760531	CH 1972-4692	19720329 <--
	US 3907782	A	19750923	US 1973-428693	19731227 <--
	SE 7414473	A	19741118	SE 1974-14473	19741118 <--
PRAI	GB 1971-8071	A	19710329		

GI For diagram(s), see printed CA Issue.

AB Quaternary pyridinium salts I (R = \geq C8 alkyl, aralkyl, alkoxyalkyl, N-alkylcarbamoylmethyl; X = MeSO₃, Br, Cl; Q = e.g. CH₂CH₂, CH:CH, NHCONH, alkylenedicarboxamido, attached in the 2-, 3-, or 4-positions on the pyridines) (110 compds.) were prepared by quaternizing the corresponding pyridines. I were used as disinfectants in dental hygiene preps. Some of the starting pyridines were also prepared


IT 39641-91-3P 39641-92-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 39641-91-3 CAPLUS
 CN Pyridinium, 1-octyl-2-[[[(1-octylpyridinium-3-yl)carbonyl]amino]methyl]-,
 dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 47709-92-2
 CMF C28 H45 N3 O



CM 2


CRN 16053-58-0
 CMF C H3 O3 S



RN 39641-92-4 CAPLUS
 CN Pyridinium, 1-decyl-2-[[[(1-decylpyridinium-3-yl)carbonyl]amino]methyl]-,
 dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 47777-39-9
 CMF C32 H53 N3 O



CM 2

CRN 16053-58-0

CMF C H3 O3 S




IT 25297-40-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(quaternization of)

RN 25297-40-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1970:66760 CAPLUS

DN 72:66760

TI Pyridylmethanides of nicotinic acid

AU Biniecki, Stanislaw; Kabzinska, Zofia

CS Akad. Med., Warsaw, Pol.

SO Acta Poloniae Pharmaceutica (1969), 26(4), 277-81

CODEN: APPHAX; ISSN: 0001-6837

DT Journal

LA Polish

GI For diagram(s), see printed CA Issue.

AB Pyridylmethyl derivs. (I) of nicotinamide (II) were synthesized for biol. screening as analogs of II and nikethamide. 2-, 3-, and 4-Cyanopyridines were prepared in 92.9, 50, and 84.3% yield, resp., by refluxing (45 min) the corresponding aldoximes with Ac₂O (0.9 g /g). Two methods were used to prepare aminomethylpyridines: 15 g cyanopyridine in 200 ml MeOH saturated with NH₃ was hydrogenated 40 hr at room temperature at 80 atm over 10 g Raney Ni and the hydrogenation product fractionated in vacuo; or 20 g aldoxime in 150 ml EtOH was treated 4 hr with stirring with 140 g Zn dust and 200 ml AcOH (no EtOH was used with the 4-isomer; 80% AcOH was used as the solvent and the addition of Zn was carried out at 40-60°), and the mixture left 24 hr and worked up. The following aminomethylpyridines were reported (isomer, b.p./mm, and % yield in the 2 methods given): 2-pyridyl, 70-2°/2, 72, 68.2; 3-pyridyl, 82-3°/4, 106-7°/14, 60, 52; 4-pyridyl, 103-4°/14, 60, 40. These (10 g), 16.5 g nicotinoyl chloride-HCl, and 100 ml anhydrous C₅H₅N refluxed 1 hr gave the following I.2HCl (isomer, % yield, m.p., m.p. of the dipicrate derivative, and m.p. or b.p. I free base given): 2-pyridyl (III), 53.2, 216-17°, 125-6°, b0.2 180-1° (n₂₀D 1.583); 3-pyridyl, 71, 219-20°, -, 106-7°; and 4-pyridyl, 56.8, 221-3°, 220-2°, 74-5°.


IT 25297-34-1P 25297-36-3P 25297-40-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 25297-34-1 CAPLUS

CN Nicotinamide, N-(2-pyridylmethyl)-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl


RN 25297-36-3 CAPLUS

CN Nicotinamide, N-(2-pyridylmethyl)-, dipicrate (8CI) (CA INDEX NAME)

CM 1

CRN 25297-40-9


CMF C12 H11 N3 O



CM 2


CRN 88-89-1

CMF C6 H3 N3 O7



RN 25297-40-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



10/501,122

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

144.08

305.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-25.55

-25.55

STN INTERNATIONAL LOGOFF AT 14:36:41 ON 28 JUN 2005